New combo aims to stall aggressive lung cancer
NCT ID NCT07141264
First seen Jan 09, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests whether combining adebrelimab (an immunotherapy) with etoposide capsules can help keep extensive-stage small cell lung cancer from progressing after initial chemotherapy. About 32 adults aged 18-75 who have not worsened after standard induction therapy will receive the drug combination until their cancer grows. The main goal is to see how long they live without the disease getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC,EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITINGXi'an, Shannxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.